Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...
The designation will provide Lundbeck with the possibility of rolling reviews and detailed guidance to streamline the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback